Patents by Inventor Frances Balkwill

Frances Balkwill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKERS FOR THE PROGNOSIS AND DIAGNOSIS OF CANCER
    Publication number: 20190284642
    Abstract: The present invention relates to biomarkers and biomarker panels useful in the prognosis and diagnosis of cancers, in particular epithelial cancers. The present invention also provides methods of treatment of patients diagnosed or having undergone diagnosis or prognosis using the biomarkers and biomarker panels of the invention. Kits for the analysis of the biomarkers and biomarker panels are also provided. The biomarker panel consists of COL11A1, CTS, ANXA6, LGALS3, ANXA1, AB13BP, COMP, COL1A1, LAMB1, CTSG, LAMA4, TNXB, FN1, AGT, FBLN2, HSPG2, COL6A6, VCAN, ANXA5, LAMC1, COL15A1 and VWF.
    Type: Application
    Filed: November 23, 2017
    Publication date: September 19, 2019
    Inventors: Frances Balkwill, Martin Knight, Conrad Bessant, Oliver Pearce, Robin Delaine-Smith, Eleni Maniati, Jun Wang
  • Cancer marker and therapeutic target
    Patent number: 10261099
    Abstract: Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: April 16, 2019
    Assignee: Cancer Research Technology Ltd.
    Inventors: Frances Balkwill, Violet Slettenaar, Julia Wilson, Yaohe Wang, Tiziana Schioppa
  • CCL22 and CCL17 cancer biomarkers
    Patent number: 10241118
    Abstract: The present invention provides methods of obtaining information relevant to monitoring and diagnosing cancer, particularly monitoring the progression or development of cancer, monitoring the response of cancer to treatment, diagnosing cancer, making a cancer prognosis, predicting the likelihood of a cancer responding to treatment and stratifying subjects having cancer. The methods involve determining the ratio of circulating CCL17 to circulating CCL22 in a sample from a subject.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: March 26, 2019
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Frances Balkwill, Chiara Berlato, Laura Fletcher
  • CANCER MARKER AND THERAPEUTIC TARGET
    Publication number: 20160223572
    Abstract: Chemokine receptor CCR4 and its ligands CCL17 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL17 and CCL22 provide anti-cancer agents.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 4, 2016
    Inventors: Frances Balkwill, Violet Slettenaar, Julia Wilson, Yaohe Wang, Tiziana Schioppa
  • CCL22 AND CCL17 CANCER BIOMARKERS
    Publication number: 20160041187
    Abstract: The present invention provides methods of obtaining information relevant to monitoring and diagnosing cancer, particularly monitoring the progression or development of cancer, monitoring the response of cancer to treatment, diagnosing cancer, making a cancer prognosis, predicting the likelihood of a cancer responding to treatment and stratifying subjects having cancer. The methods involve determining the ratio of circulating CCL17 to circulating CCL22 in a sample from a subject.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 11, 2016
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Frances BALKWILL, Chiara BERLATO, Laura FLETCHER
  • Cancer marker and therapeutic target
    Patent number: 9134293
    Abstract: Chemokine receptor CCR4 and its ligands CCL1 7 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumor progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL 17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL 17 and CCL22 provide anti-cancer agents.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: September 15, 2015
    Assignee: Cancer Research Technology Ltd.
    Inventors: Frances Balkwill, Violet Slettenaar, Julia Wilson, Yaohe Wang, Tiziana Schioppa
  • Cancer Marker and Therapeutic Target
    Publication number: 20100278844
    Abstract: Chemokine receptor CCR4 and its ligands CCL1 7 and CCL22 are used as markers for the identification and/or staging of cancer. The level of CCR4, CCL17 and CCL22 are found to increase during malignant tumour progression. CCR4, CCL17 and CCL22 are used as markers for the stratification of cancer patients according to their suitability for treatment with anti-cancer agents. Information of diagnostic character is provided by measuring the level of one or more of CCR4, CCL 17 and CCL22 present in a patient sample. Methods of treatment of cancer patients which agents that modulate the activity of CCR4, CCL17 and CCL22. Methods of screening for agents which modulate the biological activities of CCR4, CCL 17 and CCL22 provide anti-cancer agents.
    Type: Application
    Filed: September 18, 2008
    Publication date: November 4, 2010
    Inventors: Frances Balkwill, Violet Slettenaar, Julia Wilson, Yaohe Wang, Tiziana Schioppa